Type 1 diabetes mellitus (T1DM) is a growing global health concern that affects
approximately 8.5 million individuals worldwide. T1DM is characterized by an autoimmune …

Stem cell-derived islets (SC-islets) offer the potential to be an unlimited source of cells for
disease modeling and the treatment of diabetes. SC-islets can be genetically modified …

Diabetes involves the death or dysfunction of pancreatic β-cells. Analysis of bulk sequencing
from human samples and studies using in vitro and in vivo models suggest that endoplasmic …

Stem cell-derived islet therapy: is this the end of the beginning? | Nature Reviews Endocrinology
Skip to main content Thank you for visiting nature.com. You are using a browser version with …

Diabetes results from an inadequate number of insulin-producing human beta cells. There is
currently no clinically available effective means to restore beta cell mass in millions of …

Obesity-induced β cell dysfunction contributes to the onset of type 2 diabetes. Nevertheless,
elucidating epigenetic mechanisms underlying islet dysfunction at single cell level remains …

Diabetes presents a pressing healthcare crisis, necessitating innovative solutions. Organoid
technologies have rapidly advanced, leading to the emergence of bioengineering islet …

Type 1 diabetes mellitus (T1D) is an autoimmune disease caused by the destruction of
insulin-producing β-cells in the pancreas by cytotoxic T-cells. To date, there are no drugs …

Human embryonic stem cell (hESC)-derived pancreatic alpha and beta cells can be used to
develop cell replacement therapies to treat diabetes. However, recent published …

In the development of cell therapy products, immunocompromised animal models closer in
size to humans are valuable for enhancing the translatability of in vivo findings to clinical …